News | March 18, 2009

Partnership for Prevention Advocates Daily Aspirin Use to Prevent Heart Attack, Stroke

March 18, 2009 - The U.S. Preventive Services Task Force (USPSTF) found that regular aspirin use reduces first heart attacks in men and first strokes in women and recommends daily aspirin use for certain patient populations.
The recommendation applies to men between the ages of 45 and 79 and to women 55 to 79. Aspirin should be used when the benefits outweigh the harms for potential gastrointestinal bleeding.
The new recommendation underscores the importance of healthcare providers discussing aspirin use with patients. A 2007 study sponsored by the American College of Preventive Medicine found that the factor most strongly associated with appropriate aspirin use is a conversation about aspirin between a patient and healthcare provider. The recommendation will help clinicians assess individuals' risk for heart disease and stroke, and it gives clinicians guidance about age- and gender-specific benefits and harms of aspirin use.
A separate study by Partnership for Prevention found that if 90 percent of people who could benefit from aspirin actually took the daily dose, an additional 45,000 lives would be saved each year.
The National Committee for Quality Assurance, which measures the quality of care provided by health plans, recently recognized that aspirin use is effective in reducing cardiovascular events. To encourage appropriate aspirin use, NCQA has proposed that health plans measure their members' use of aspirin as well as the extent to which clinicians discuss aspirin use with patients.
Partnership for Prevention has established a Task Force on Appropriate Aspirin Use to encourage appropriate use of aspirin to prevent heart attacks and strokes.
"The updated USPSTF recommendation emphasizes the importance of considering the potential benefits and downsides of using aspirin for cardiovascular prevention. It's clear that discussing aspirin use with patients in the targeted age groups should become standard practice for clinicians," said Michael Pignone, M.D., a member of Partnership's Task Force and chief of general internal medicine at the University of North Carolina.
Partnership for Prevention is a non-partisan, non-profit organization of business, healthcare, and government leaders who are working to make disease prevention and health promotion a higher priority in the nation's health policies and programs
Source: Partnership for Prevention
For more information: www.prevent.org


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now